Results of patient-reported outcome in Japanese patients with multiple sclerosis: Evaluation of the severity and progression of gait disability

Objective To evaluate the degree of severity and disability progression in Japanese patients with multiple sclerosis (MS) using descriptive study methods. Methods Postal questionnaires were sent to patients through three Japanese MS patients' associations. Survey participants were asked to eval...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical & experimental neuroimmunology 2015-08, Vol.6 (3), p.275-280
Hauptverfasser: Nakashima, Ichiro, Harada, Naozumi, Nakaya, Fuyuki
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 280
container_issue 3
container_start_page 275
container_title Clinical & experimental neuroimmunology
container_volume 6
creator Nakashima, Ichiro
Harada, Naozumi
Nakaya, Fuyuki
description Objective To evaluate the degree of severity and disability progression in Japanese patients with multiple sclerosis (MS) using descriptive study methods. Methods Postal questionnaires were sent to patients through three Japanese MS patients' associations. Survey participants were asked to evaluate their disability and MS severity based on two scales: the Patient Determined Disease Steps (PDDS) and the Short Form-8 Health Survey. Results A total of 789 MS patients were surveyed. Approximately 45% of patients had gait disability (PDDS score of 3) or higher. Patients with a higher age of MS onset had rapid progression of disease. The mean duration from first symptom of MS to treatment initiation was 4.5 years. The time to treatment initiation was longer for the younger onset group, ≤29 years-of-age, than that of the older onset group, ≥40 years-of-age (6.2 years vs 2.2 years, respectively). The PDDS showed two-stage disability progression: while progression time to a PDDS score of 2 varied, progression time from a PDDS score of 2 to a score of 4 was similar across the participants. Conclusions Based on the patient-reported disability progression of MS, we showed that the possibility of severity and MS disease progression between Japanese and Western countries might be similar. The PDDS could be a useful alternative to assess MS disability.
doi_str_mv 10.1111/cen3.12216
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1700594389</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3766192391</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2646-55982d27732a82068877071da90949b3574daa3ce1ea26bd0e4b5ba08dfd12f63</originalsourceid><addsrcrecordid>eNpNkNtKw0AQhoMoWLQ3PsGCd0LqHpJs4p2UHixFpSiCN8smO6mraRJ3N9U-ha_s1lZxbmbg_-b0B8EZwQPi47KAmg0IpSQ5CHqEx1lIsoQc_quPg761r9gHS9OIR73gawG2q5xFTYla6TTULjTQNsaBQk3nimYFSNdoJltZg4VfyKIP7V7QyvfqtgJkiwpMY7W9QqO1rDpPNfV2qHvxIqzBaLdBslaoNc3SgLV7fSm1Q0pbmevKI6fBUSkrC_19Pgkex6OH4TSc301uhtfzsKBJlIRxnKVUUc4ZlSnFSZpyjjlRMsNZlOUs5pGSkhVAQNIkVxiiPM4lTlWpCC0TdhKc7-b6c947sE68Np2p_UpBOMZxFrE089TFjir8b9ZAKVqjV9JsBMFi67nYei5-PPdwuIO1dfD5R0rzJhLOeCyebidiGi3G93g2FM_sG-aLhgI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1700594389</pqid></control><display><type>article</type><title>Results of patient-reported outcome in Japanese patients with multiple sclerosis: Evaluation of the severity and progression of gait disability</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Nakashima, Ichiro ; Harada, Naozumi ; Nakaya, Fuyuki</creator><creatorcontrib>Nakashima, Ichiro ; Harada, Naozumi ; Nakaya, Fuyuki</creatorcontrib><description>Objective To evaluate the degree of severity and disability progression in Japanese patients with multiple sclerosis (MS) using descriptive study methods. Methods Postal questionnaires were sent to patients through three Japanese MS patients' associations. Survey participants were asked to evaluate their disability and MS severity based on two scales: the Patient Determined Disease Steps (PDDS) and the Short Form-8 Health Survey. Results A total of 789 MS patients were surveyed. Approximately 45% of patients had gait disability (PDDS score of 3) or higher. Patients with a higher age of MS onset had rapid progression of disease. The mean duration from first symptom of MS to treatment initiation was 4.5 years. The time to treatment initiation was longer for the younger onset group, ≤29 years-of-age, than that of the older onset group, ≥40 years-of-age (6.2 years vs 2.2 years, respectively). The PDDS showed two-stage disability progression: while progression time to a PDDS score of 2 varied, progression time from a PDDS score of 2 to a score of 4 was similar across the participants. Conclusions Based on the patient-reported disability progression of MS, we showed that the possibility of severity and MS disease progression between Japanese and Western countries might be similar. The PDDS could be a useful alternative to assess MS disability.</description><identifier>ISSN: 1759-1961</identifier><identifier>EISSN: 1759-1961</identifier><identifier>DOI: 10.1111/cen3.12216</identifier><language>eng</language><publisher>Ube: Blackwell Publishing Ltd</publisher><subject>disease progression ; Multiple sclerosis ; Patient Determined Disease Steps ; Patients ; questionnaires</subject><ispartof>Clinical &amp; experimental neuroimmunology, 2015-08, Vol.6 (3), p.275-280</ispartof><rights>Copyright © 2015 Japanese Society for Neuroimmunology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2646-55982d27732a82068877071da90949b3574daa3ce1ea26bd0e4b5ba08dfd12f63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Nakashima, Ichiro</creatorcontrib><creatorcontrib>Harada, Naozumi</creatorcontrib><creatorcontrib>Nakaya, Fuyuki</creatorcontrib><title>Results of patient-reported outcome in Japanese patients with multiple sclerosis: Evaluation of the severity and progression of gait disability</title><title>Clinical &amp; experimental neuroimmunology</title><addtitle>Clin Exp Neuroimmunol</addtitle><description>Objective To evaluate the degree of severity and disability progression in Japanese patients with multiple sclerosis (MS) using descriptive study methods. Methods Postal questionnaires were sent to patients through three Japanese MS patients' associations. Survey participants were asked to evaluate their disability and MS severity based on two scales: the Patient Determined Disease Steps (PDDS) and the Short Form-8 Health Survey. Results A total of 789 MS patients were surveyed. Approximately 45% of patients had gait disability (PDDS score of 3) or higher. Patients with a higher age of MS onset had rapid progression of disease. The mean duration from first symptom of MS to treatment initiation was 4.5 years. The time to treatment initiation was longer for the younger onset group, ≤29 years-of-age, than that of the older onset group, ≥40 years-of-age (6.2 years vs 2.2 years, respectively). The PDDS showed two-stage disability progression: while progression time to a PDDS score of 2 varied, progression time from a PDDS score of 2 to a score of 4 was similar across the participants. Conclusions Based on the patient-reported disability progression of MS, we showed that the possibility of severity and MS disease progression between Japanese and Western countries might be similar. The PDDS could be a useful alternative to assess MS disability.</description><subject>disease progression</subject><subject>Multiple sclerosis</subject><subject>Patient Determined Disease Steps</subject><subject>Patients</subject><subject>questionnaires</subject><issn>1759-1961</issn><issn>1759-1961</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpNkNtKw0AQhoMoWLQ3PsGCd0LqHpJs4p2UHixFpSiCN8smO6mraRJ3N9U-ha_s1lZxbmbg_-b0B8EZwQPi47KAmg0IpSQ5CHqEx1lIsoQc_quPg761r9gHS9OIR73gawG2q5xFTYla6TTULjTQNsaBQk3nimYFSNdoJltZg4VfyKIP7V7QyvfqtgJkiwpMY7W9QqO1rDpPNfV2qHvxIqzBaLdBslaoNc3SgLV7fSm1Q0pbmevKI6fBUSkrC_19Pgkex6OH4TSc301uhtfzsKBJlIRxnKVUUc4ZlSnFSZpyjjlRMsNZlOUs5pGSkhVAQNIkVxiiPM4lTlWpCC0TdhKc7-b6c947sE68Np2p_UpBOMZxFrE089TFjir8b9ZAKVqjV9JsBMFi67nYei5-PPdwuIO1dfD5R0rzJhLOeCyebidiGi3G93g2FM_sG-aLhgI</recordid><startdate>20150801</startdate><enddate>20150801</enddate><creator>Nakashima, Ichiro</creator><creator>Harada, Naozumi</creator><creator>Nakaya, Fuyuki</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope></search><sort><creationdate>20150801</creationdate><title>Results of patient-reported outcome in Japanese patients with multiple sclerosis: Evaluation of the severity and progression of gait disability</title><author>Nakashima, Ichiro ; Harada, Naozumi ; Nakaya, Fuyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2646-55982d27732a82068877071da90949b3574daa3ce1ea26bd0e4b5ba08dfd12f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>disease progression</topic><topic>Multiple sclerosis</topic><topic>Patient Determined Disease Steps</topic><topic>Patients</topic><topic>questionnaires</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakashima, Ichiro</creatorcontrib><creatorcontrib>Harada, Naozumi</creatorcontrib><creatorcontrib>Nakaya, Fuyuki</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>Clinical &amp; experimental neuroimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakashima, Ichiro</au><au>Harada, Naozumi</au><au>Nakaya, Fuyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Results of patient-reported outcome in Japanese patients with multiple sclerosis: Evaluation of the severity and progression of gait disability</atitle><jtitle>Clinical &amp; experimental neuroimmunology</jtitle><addtitle>Clin Exp Neuroimmunol</addtitle><date>2015-08-01</date><risdate>2015</risdate><volume>6</volume><issue>3</issue><spage>275</spage><epage>280</epage><pages>275-280</pages><issn>1759-1961</issn><eissn>1759-1961</eissn><abstract>Objective To evaluate the degree of severity and disability progression in Japanese patients with multiple sclerosis (MS) using descriptive study methods. Methods Postal questionnaires were sent to patients through three Japanese MS patients' associations. Survey participants were asked to evaluate their disability and MS severity based on two scales: the Patient Determined Disease Steps (PDDS) and the Short Form-8 Health Survey. Results A total of 789 MS patients were surveyed. Approximately 45% of patients had gait disability (PDDS score of 3) or higher. Patients with a higher age of MS onset had rapid progression of disease. The mean duration from first symptom of MS to treatment initiation was 4.5 years. The time to treatment initiation was longer for the younger onset group, ≤29 years-of-age, than that of the older onset group, ≥40 years-of-age (6.2 years vs 2.2 years, respectively). The PDDS showed two-stage disability progression: while progression time to a PDDS score of 2 varied, progression time from a PDDS score of 2 to a score of 4 was similar across the participants. Conclusions Based on the patient-reported disability progression of MS, we showed that the possibility of severity and MS disease progression between Japanese and Western countries might be similar. The PDDS could be a useful alternative to assess MS disability.</abstract><cop>Ube</cop><pub>Blackwell Publishing Ltd</pub><doi>10.1111/cen3.12216</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1759-1961
ispartof Clinical & experimental neuroimmunology, 2015-08, Vol.6 (3), p.275-280
issn 1759-1961
1759-1961
language eng
recordid cdi_proquest_journals_1700594389
source Wiley Online Library Journals Frontfile Complete
subjects disease progression
Multiple sclerosis
Patient Determined Disease Steps
Patients
questionnaires
title Results of patient-reported outcome in Japanese patients with multiple sclerosis: Evaluation of the severity and progression of gait disability
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T09%3A02%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Results%20of%20patient-reported%20outcome%20in%20Japanese%20patients%20with%20multiple%20sclerosis:%20Evaluation%20of%20the%20severity%20and%20progression%20of%20gait%20disability&rft.jtitle=Clinical%20&%20experimental%20neuroimmunology&rft.au=Nakashima,%20Ichiro&rft.date=2015-08-01&rft.volume=6&rft.issue=3&rft.spage=275&rft.epage=280&rft.pages=275-280&rft.issn=1759-1961&rft.eissn=1759-1961&rft_id=info:doi/10.1111/cen3.12216&rft_dat=%3Cproquest_cross%3E3766192391%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1700594389&rft_id=info:pmid/&rfr_iscdi=true